Sanofi returned 54% of its gross sales to payers through rebates in 2020, marking the third consecutive year the company paid more than 50% of gross revenue in rebates. The French pharmaceutical company released its fifth annual pricing report on 3 March, fulfilling a commitment by the company to be more transparent about drug pricing.
The top-line takeaway from the report is that Sanofi's US average aggregate list price across the commercial portfolio increased 0.2%...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?